Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

• ClinicalTrials.gov Identifier: NCT05316155
• Recruitment Status: Recruiting
• First Posted: April 7, 2022
• Last Update Posted: April 24, 2024
• Sponsor: Janssen Research & Development, LLC
• Information provided by (Responsible Party): Janssen Research & Development, LLC

Tracking Information

• First Submitted Date: March 30, 2022
• First Posted Date: April 7, 2022
• Last Update Posted Date: April 24, 2024
• Actual Study Start Date: April 11, 2022
• Estimated Primary Completion Date: March 30, 2028 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 30, 2022)

• Number of Participants with Adverse Events (AEs) [ Time Frame: Up to 5 years 3 months ]
  An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
• Number of Participants with AEs by Severity [ Time Frame: Up to 5 years 3 months ]
  Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
• Number of Participants with Dose-limiting Toxicity (DLT) [ Time Frame: Up to 28 days ]
  Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: September 8, 2023)

• Plasma Concentration of Erdafitinib [ Time Frame: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks ]
  Plasma concentration of Erdafitinib will be reported.
• Urine Concentration of Erdafitinib [ Time Frame: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks ]
  Urine concentration of Erdafitinib will be reported.
• Cohorts 1 and 2: Recurrence-Free Survival (RFS) [ Time Frame: Up to 5 years 3 months ]
  RFS is defined as the time from start of treatment to the first detection of any new high-grade bladder cancer or upper tract urothelial carcinoma or positive urine cytology.
• Cohort 3 and 5: Complete Response (CR) Rate [ Time Frame: At 3 months ]
  CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology.
• Cohort 3 and 5: Duration of CR [ Time Frame: Up to 5 years 3 months ]
  Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.
• Cohort 4: Pathological Complete Response (pCR) Rate [ Time Frame: Up to 8 weeks ]
  pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0).
• Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0) [ Time Frame: Up to 8 weeks ]
  pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease.
• Cohort 4: Rate of downstaging to Less than (<) pT2 [ Time Frame: Up to 8 weeks ]
  Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2.

Original Secondary Outcome Measures (submitted: March 30, 2022)

• Plasma Concentration of Erdafitinib [ Time Frame: Cohorts 1 and 3: up to 6 months; Cohort 2 and 4: up to 8 weeks ]
  Plasma concentration of Erdafitinib will be reported.
• Urine Concentration of Erdafitinib [ Time Frame: Cohorts 1 and 3: up to 6 months; Cohort 2 and 4: up to 8 weeks ]
  Urine concentration of Erdafitinib will be reported.
• Cohorts 1 and 2: Recurrence-Free Survival (RFS) [ Time Frame: Up to 5 years 3 months ]
  RFS is defined as the time from start of treatment to the first detection of high-grade Ta or T1 bladder cancer or positive urine cytology.
• Cohort 3: Complete Response (CR) Rate [ Time Frame: Up to 5 years 3 months ]
  CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology.
• Cohort 3: Duration of CR [ Time Frame: Up to 5 years 3 months ]
  Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.
• Cohort 4: Pathological Complete Response (pCR) Rate [ Time Frame: Up to 5 years 3 months ]
  pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0).
• Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0) [ Time Frame: Up to 5 years 3 months ]
  pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease.
• Cohort 4: Rate of downstaging to Less than (<) pT2 [ Time Frame: Up to 5 years 3 months ]
  Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
• Official Title: Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non- Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
• Brief Summary: The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D.
• Detailed Description: Bladder cancer is one of the most common malignancy worldwide, and non-muscle invasive (NMIBC) requires intensive regimens of frequent monitoring and local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-muscle invasive or muscle invasive bladder cancer with activating fibroblast growth factor receptor (FGFR) mutations or fusions. Erdafitinib is a pan-FGFR inhibitor with demonstrated clinical activity when administered orally in patients with solid tumors, including bladder cancer, with FGFR genetic alterations. The Erdafitinib intravesical delivery system is designed to provide release of Erdafitinib in the bladder to treat localized bladder cancer, while reducing systemic toxicities. The study consists of a screening phase, a treatment phase, and a follow-up phase. Total duration of the study is 5 years 3 months.
• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Urinary Bladder Neoplasms
• Receptors, Fibroblast Growth Factor

Intervention

Drug: Erdafitinib Intravesical Delivery System

Erdafitinib intravesical delivery system will be administered.

Other Name: JNJ-42756493

Study Arms

• Experimental: Part 1: Dose Escalation
  Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2.
  Intervention: Drug: Erdafitinib Intravesical Delivery System
• Experimental: Part 2: Dose Expansion
  Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.
  Intervention: Drug: Erdafitinib Intravesical Delivery System
• Experimental: Part 3: RP2D Dose Expansion
  Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity.
  Intervention: Drug: Erdafitinib Intravesical Delivery System

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: February 28, 2024): 112
• Original Estimated Enrollment (submitted: March 30, 2022): 92
• Estimated Study Completion Date: March 31, 2028
• Estimated Primary Completion Date: March 30, 2028 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Muscle-invasive or recurrent, non-muscle-invasive urothelial carcinoma of the bladder
• For selected Cohorts: Activating tumor pan-fibroblast growth factor receptor (FGFR) mutation or fusion, as determined by local or central testing, approved by the sponsor prior to the start of study treatment. Local tissue-based results (if already existing) from next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests performed in Clinical Laboratory Improvement Amendments (CLIA) -certified or equivalent laboratories, or results from commercially available PCR or NGS tests
• Cohorts 1 and 2: Bacillus Calmette-Guérin (BCG) experienced, or participants with no BCG experience because BCG was not available as a treatment option in the participant's location within the previous 2 years and is currently unavailable. Participants who received an abbreviated course of BCG due to toxicity are still eligible
• Cohort 1 only: Refuses or is not eligible for radical cystectomy (RC)
• Cohorts 2 and 4: Willing and eligible for RC

Exclusion Criteria:

• Concurrent extra-vesical (that is, urethra, ureter, renal pelvis) transitional cell carcinoma of the urothelium
• Prior treatment with an pan-fibroblast growth factor receptor (FGFR) inhibitor
• Received pelvic radiotherapy <=6 months prior to the planned start of study treatment. If received pelvic radiotherapy greater than (>)6 months prior to the start of study treatment, there must be no cystoscopic evidence of radiation cystitis
• Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe use of Erdafitinib intravesical delivery system
• Indwelling urinary catheter. Intermittent catheterization is acceptable

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Study Contact; 844-434-4210; Participate-In-This-Study@its.jnj.com

• Listed Location Countries: Germany, Korea, Republic of, Netherlands, Spain, United States
• Removed Location Countries: France

Administrative Information

• NCT Number: NCT05316155
• Other Study ID Numbers: CR109115; 42756493BLC1003 ( Other Identifier: Janssen Research & Development, LLC ); 2021-004144-22 ( EudraCT Number )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
• URL: https://www.janssen.com/clinical-trials/transparency

• Current Responsible Party: Janssen Research & Development, LLC
• Original Responsible Party: Same as current
• Current Study Sponsor: Janssen Research & Development, LLC
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Janssen Research & Development, LLC Clinical Trial; Janssen Research & Development, LLC

• PRS Account: Janssen Research & Development, LLC
• Verification Date: April 2024